arrow
I

Isabel Chirivella

universidad de valencia
H指数:23
被引数:2,577

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors” [Eur. Urol. Open Sci. 70 (2024) 86–90]

勘误:“接受雄激素受体通路抑制剂治疗的有转移性激素敏感性前列腺癌患者中RB1、PTEN和TP53基因的预后表达特征”[Eur. Urol. Open Sci. 70 (2024) 86–90]

2025-06-040
OA
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]

勘误:关于“基于RB1、PTEN和TP53在转移性激素敏感性前列腺癌患者中开发并独立验证预后基因表达签名”[Eur. Urol. Oncol. 7 (2024) 954–964]

2025-05-010
PRE
Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors

雄激素受体途径抑制剂治疗的转移性激素敏感型前列腺癌患者RB1、PTEN和TP53基因的预后表达特征

2024-12-011
PRE
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
2024-08-014
OA
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

223镭治疗的转移性去势抵抗性前列腺癌患者的骨代谢生物标志物和生存率的前瞻性评估: PRORADIUM研究

2024-06-012
PRE
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers
2023-05-014
PRE
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study
2021-09-0719
OAAI
TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer
2021-09-010
OAAI
PRORADIUM: Prospective analysis of the impact of germline mutations in homologous recombination (HR) genes on the response to radium-223 for metastatic castration resistant prostate cancer (mCRPC)
2021-09-013
OAAI
Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations
2019-06-198
OAAI
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

肾癌靶向治疗毒性管理指南实施对临床实践的影响。protect-2研究

2016-02-228
OAAI
Effectiveness of 2nd-line and subsequent therapies after pazopanib (Paz) in patients (pt) with metastatic renal cell carcinoma (mRCC): Final results of the SPAZO study (SOGUG)
2015-09-010
PREAI